Manufacturing Expansion & Investment - Eli Lilly is investing $5 billion in a new US manufacturing site in Virginia, specializing in active pharmaceutical ingredients (API) and drug product for cancer, autoimmune diseases, and advanced therapies [1] - The new factory will enable Eli Lilly to produce targeted chemotherapies or antibody drug conjugates for the first time [1] - Eli Lilly's goal is to increase manufacturing capacity and bring more manufacturing work in-house [2] - Since 2020, Eli Lilly's total manufacturing investments amount to $50 billion, including a previously announced $27 billion investment in four new sites [4] Tax & Economic Factors - Lower US corporate tax rates (21%) influenced Eli Lilly's decision to build the API site in the US [2][3] - Previously, a 35% corporate tax rate made locating API facilities outside the US more financially attractive [3] Supply Chain & Tariffs - Eli Lilly aims to build a balanced and redundant supply chain to ensure medicine availability for patients [5] - The company is monitoring tariff developments but believes they will not significantly alter its overall strategy [5][6]